Navigation Links
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Date:2/7/2013

WORCESTER, Mass. and TORONTO, Feb. 7, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today provided an overview of the current pipeline and potential of its wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com). While the Company is currently in a late Phase IIb trial of a very promising new immunotherapy for early breast cancer (AE37), the Company has made concrete headway in demonstrating a robust pipeline for AE37 indications beyond breast cancer, as well as for the technology behind it. Immediately behind its Phase III-ready breast cancer program, the Company has completed a Phase I prostate cancer trial and established a protocol for Phase II. While Herceptin targets the same tumor-associated protein as does AE37 therapy, Herceptin is not approved for breast cancer patients with low levels of HER2 expression, limiting Herceptin treatment to roughly 25% of breast cancer patients. Low levels of HER2 protein have been shown on several cancers, including men with prostate cancer. AE37 is being further researched in this larger population of patients whose tumors express only low levels of HER2.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)

While breast and prostate cancers are the initial indications being investigated for AE37, nearly all cancers of the gastrointestinal tract as well as lung, ovarian, bladder, and other cancers also express low levels of HER2. AE37 future research may help establish its role in many cancers in addition to breast and prostate cancer. A unique aspect of Antigen Express technology, which has enabled the promising results obtained so far from the AE37 Phase IIb trial in early breast cancer, is the Ii-Key technology
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MIAMI , Nov. 22, 2014  New data ... for the most common form of female sexual dysfunction, ... cognitive function or driving performance in premenopausal women when ... Sexual Medicine Society of North America,s ... Miami . SMSNA accepted ...
(Date:11/22/2014)... , Nov. 21, 2014 Statistics released from ... drunk driving increase astronomically during the holidays, beginning with ... many cities. The data, highlighted ... Systems as part of their annual Sober ... a picture of high-risk drinking and increased rates of ...
(Date:11/22/2014)... Nov. 21, 2014 Many power shifts ... growing influence of patients in the biopharmaceutical market ... Now, more than ever, understanding how to effectively ... products is essential. According to ... benchmarked companies spent about two-thirds of their patient-focused ...
Breaking Medicine Technology:Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3Alarming Stats Show Holiday Drinking an Issue for Many 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... Oct. 21 WebMD Health Corp. (Nasdaq: WBMD ), ... UK,s leading pharmacy-led health and beauty retailer, today announced the ... Kingdom. The strategic partnership with Boots UK expands WebMD,s presence ... wellness issues that are most relevant to them. , WebMD ...
... 21 IRIDEX Corporation (Nasdaq: IRIX ) ... laser photocoagulator solution, which will be featured at ... meeting in San Francisco. , "Our new ... the multi-wavelength photocoagulator market segment with a flexible, ...
Cached Medicine Technology:WebMD Launches New Consumer Health Portal in the U.K. 2WebMD Launches New Consumer Health Portal in the U.K. 3IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology 2
(Date:11/24/2014)... 2014 The Mesothelioma Applied Research ... International Symposium on Malignant Mesothelioma from March 2nd through ... sessions will take place on the campus of the ... a community dinner and an awards ceremony, will be ... cover a range of topics about pleural and peritoneal ...
(Date:11/24/2014)... 2014 A new sports massage ... pain-relief service and massage therapy provider, announced it ... This newest sports massage is a ... between traditional sports massage and ESM is that ... very own "reset button,” and ESM can increase ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 SWAccessControl.com ... locks. As a matter of fact, the company is a ... its brand new magnetic locks are available at discounted prices, ... our new range of magnetic locks. This time, all of ... are popular at home and abroad, so I have confidence ...
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
Breaking Medicine News(10 mins):Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4
... cell therapy can be used successfully to treat heart attacks//. ... that it is possible to treat the heart attacks of ... two months, stem cells harvested from another pig?s bone marrow ... and repaired damaged heart muscle by 50 percent to 75 ...
... mannose for their metabolism// and growth different from human ... McConville and his research team from Bio21 Institute at ... to control the spread of the parasite Leishmania in ... in the blood for their metabolism and growth and ...
... a report saying that wearing high heels may be ... etc., ,Jarl Flensmark says high heels cause their ... normal walking never does. That could prevent neuro-receptors in ... compound necessary for mental well-being., ,"During walking, synchronized ...
... People working in the salt factories may be at a ... course of work. ,Scientists from the Desert Medicine ... of workers in two salt milling factories in Rajasthan., ... to a salt milling plant and were directly involved in ...
... mind the image of a medication. Rather it is the ... as a respite in the sweltering heat and charms one ... found to fight tumours and make cancer fret. Nutritionally mango ... ,Now research conducted at Indian Toxicology Research Institute (ITRC), ...
... Pharmaceutical Pricing Authority (NPPA) has been working// on bringing ... negotiations with the manufacturers and has finally succeeded. According ... agreed to bring about a price reduction ranging between ... a personal hearing to explain the reasons for steep ...
Cached Medicine News:Health News:Stem Cell Therapy For Treating Heart Attacks 2Health News:Metabolism cycle of Kala-Azar parasite revealed 2Health News:Wearing High Heels May Be Dangerous To Health, 2Health News:Wearing High Heels May Be Dangerous To Health, 3Health News:Inhaling Salt Can Lead To Hypertension 2
... that need an advanced ... Vision,Premier Holter System provides ... Vision Premier system,adds expanded ... comprehensive list of diagnostic,codes ...
... EK-10 single-channel,electrocardiograph features a ... keypad. It provides the,necessary ... quick and,accurate diagnosis. The ... a built in handle ...
... three contrast levels (high, 9.5 % and 6%) ... test is designed to detect very subtle changes ... evaluation or due to refractive surgery. The upper ... contrast and acuity levels as the lower two ...
... is used to evaluate both low contrast acuity ... and 12.5%) of LogMAR acuity (20/16 to 20/100) ... as the two spatial frequencies of 6 and ... for cataract documentation because eye doctors can document ...
Medicine Products: